• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Histopathologic impacts of everolimus introduction on kidney transplant recipients.

作者信息

Nakamura T, Ushigome H, Takata T, Nakao T, Harada S, Koshino K, Suzuki T, Ito T, Nobori S, Yoshimura N

机构信息

Department of Organ Transplantation and General Surgery, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan.

Department of Organ Transplantation and General Surgery, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan.

出版信息

Transplant Proc. 2015 Apr;47(3):630-4. doi: 10.1016/j.transproceed.2014.09.180.

DOI:10.1016/j.transproceed.2014.09.180
PMID:25891700
Abstract

BACKGROUND

Introduction of everolimus (RAD) has been established as a new immunosuppressive medication for kidney transplant (KT) recipients. Administration of RAD is capable of reducing the dosage of coadministrated calcineurin inhibitors (CNI). However, histological investigations have rarely been performed.

METHODS

To clarify histopathologic effects of RAD, a total of 9 adult KT recipients were enrolled (RAD group, n = 5; Mycophenolate mofetil (MMF) group, n = 4). Renal graft biopsies had been performed at 3 weeks and 1 year following KT.

RESULTS

There were no differences in 1-, 3-, and 5-year graft survival rates (RAD group: 100%, 100%, and 80%, respectively; MMF group: 100%, 100%, and 75%, respectively), and patient survival between the 2 groups (no deaths during the 5 years post-transplantation). Interestingly, although 2 patients in the RAD group had developed CNI nephrotoxicity clinically, renal biopsies had proven no CNI-related lesions 1 year later, which might be due to the reduction in CNI. On the other hand, 1 patient, in the MMF group, had been diagnosed histologically with new-onset CNI nephrotoxicity 1 year following KT. Importantly, the frequency and mean arteriolar hyalinosis (ah) scores, which reflect CNI nephrotoxicity, were significantly higher in the MMF group at 1-year biopsy (P < .05, P < .0001). Two patients in the RAD group improved their ah scores between 3 weeks and 1 year.

CONCLUSIONS

Pathological findings revealed that reversible CNI nephrotoxicity can be improved by RAD with reduced CNI maintenance therapy. It is reasonable to believe, therefore, that introduction of RAD is useful for patients who have been diagnosed with CNI nephrotoxicity.

摘要

相似文献

1
Histopathologic impacts of everolimus introduction on kidney transplant recipients.
Transplant Proc. 2015 Apr;47(3):630-4. doi: 10.1016/j.transproceed.2014.09.180.
2
Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.稳定的ABO血型不相容肾移植受者从霉酚酸酯联合标准剂量钙调神经磷酸酶抑制剂(CNIs)转换为依维莫司联合极低剂量CNIs的短期初步研究。
Clin Transplant. 2014 Jan;28(1):80-7. doi: 10.1111/ctr.12281. Epub 2013 Dec 11.
3
Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.在初治肾移植受者中早期引入依维莫司与低暴露量环孢素A联合使用的安全性和有效性。
Transplantation. 2015 Jan;99(1):180-6. doi: 10.1097/TP.0000000000000225.
4
Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.在接受监测活检的肾移植受者中,四种不同的无长期类固醇治疗免疫抑制方案的比较:五年结果
Transpl Immunol. 2008 Nov;20(1-2):32-42. doi: 10.1016/j.trim.2008.08.005. Epub 2008 Sep 4.
5
Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation.依维莫司联合霉酚酸酯作为肝移植初始免疫抑制治疗
Transplant Proc. 2015 Jan-Feb;47(1):90-2. doi: 10.1016/j.transproceed.2014.11.005.
6
Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.儿童实体器官移植受者中钙调神经磷酸酶抑制剂诱导的肾毒性的治疗策略。
Pediatr Transplant. 2006 Sep;10(6):721-9. doi: 10.1111/j.1399-3046.2006.00577.x.
7
SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.基于西罗莫司的免疫抑制与慢性钙调神经磷酸酶抑制剂肾毒性的小儿肾移植受者中钙调神经磷酸酶抑制剂最小化的比较
Pediatr Transplant. 2006 Aug;10(5):593-601. doi: 10.1111/j.1399-3046.2006.00526.x.
8
Conversion to everolimus in kidney transplant recipients: to believe or not believe?肾移植受者转换为依维莫司治疗:信还是不信?
Transplant Proc. 2012 Dec;44(10):2966-70. doi: 10.1016/j.transproceed.2012.06.072.
9
Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.依维莫司与霉酚酸酯预防初发肾移植受者排斥反应的比较:一项为期3年的随机、多中心、III期研究。
Transplantation. 2005 Jul 27;80(2):244-52. doi: 10.1097/01.tp.0000164352.65613.24.
10
Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.肾移植采用西罗莫司和霉酚酸酯为基础的免疫抑制治疗:与钙调神经磷酸酶抑制剂药物相比的随机前瞻性试验5年结果
Transplantation. 2007 Apr 15;83(7):883-92. doi: 10.1097/01.tp.0000258586.52777.4c.